ArticleBMC ophthalmology2025
Clinical effects of the 2021 update of the Turkish retinopathy of prematurity guideline.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to assess the impact of the 2021 update of the Turkish Retinopathy of Prematurity (ROP) Guidelines within a tertiary care university clinic.
methodsA retrospective evaluation was conducted on the medical records of premature infants (n = 366) who underwent ROP screening between September 2021 and June 2024 and attended regular follow-up visits. Among these infants, 217 (59.28%) met the previously established ROP screening criteria. A comprehensive analysis was performed on a dataset of 149 (40.71%) additional screenable premature infants (gestational age > 32 weeks and birth weight > 1500 g) according to the revised criteria.
resultsA total of 149 patients were included in the study. Among these patients, 65 (43.6%) were female and 84 (56.4%) were male. The mean gestational age was 33.85 ± 1.17 weeks, and the mean birth weight was 2051.07 ± 399.63 g. During the follow-up period, 17 patients (11.4%) developed ROP, with four patients (2.7%) exhibiting treatment-requiring ROP. The mean gestational age at delivery for patients who developed ROP was 33.70 ± 1.24 weeks, and their mean birth weight was 2155.65 ± 368.75 g. No significant differences were observed between these patients and those who did not develop ROP (p = 0.627, p = 0.521, respectively).
conclusionsThe recent update to the Turkish ROP guideline has the potential to increase the incidence of screening among infants by up to 68.6%. However, the finding that 2.7% of screened infants developed treatment-requiring ROP underscores the importance of this guideline update.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.